Common Contracts

3 similar Credit Agreement contracts by Jazz Pharmaceuticals PLC

This AMENDMENT NO. 3, dated as of November 26, 2024 (this “Amendment”), to the Credit Agreement, dated as of May 5, 2021 (as amended by that certain LIBOR Successor Rate Conforming Changes Amendment, dated as of June 7, 2023, that certain Amendment...
Credit Agreement • November 26th, 2024 • Jazz Pharmaceuticals PLC • Pharmaceutical preparations • Delaware

WHEREAS, Jazz UK (an indirect subsidiary of Parent) (and/or, at Jazz UK’s election, Parent and/or the DR Nominee (as defined in the Transaction Agreement)) will acquire the entire issued and to be issued share capital of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (“GW Pharma”) by means of a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the “Acquisition”) pursuant to a Transaction Agreement, dated as of February 3, 2021 (the “Transaction Agreement”), by and among Parent, Jazz UK and GW Pharma; and

AMENDMENT NO. 2
Credit Agreement • July 22nd, 2024 • Jazz Pharmaceuticals PLC • Pharmaceutical preparations • Delaware

WHEREAS, Jazz UK (an indirect subsidiary of Parent) (and/or, at Jazz UK’s election, Parent and/or the DR Nominee (as defined in the Transaction Agreement)) will acquire the entire issued and to be issued share capital of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (“GW Pharma”) by means of a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the “Acquisition”) pursuant to a Transaction Agreement, dated as of February 3, 2021 (the “Transaction Agreement”), by and among Parent, Jazz UK and GW Pharma; and

AMENDMENT NO. 1
Credit Agreement • January 25th, 2024 • Jazz Pharmaceuticals PLC • Pharmaceutical preparations • Delaware

WHEREAS, Jazz UK (an indirect subsidiary of Parent) (and/or, at Jazz UK’s election, Parent and/or the DR Nominee (as defined in the Transaction Agreement)) will acquire the entire issued and to be issued share capital of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (“GW Pharma”) by means of a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the “Acquisition”) pursuant to a Transaction Agreement, dated as of February 3, 2021 (the “Transaction Agreement”), by and among Parent, Jazz UK and GW Pharma; and